Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome

The effect of thrombophilic mutations in the development of thrombosis in patients with antiphospholipid syndrome (APS) has been extensively investigated. Factor XIII (FXIII) Val34Leu polymorphism is a newly described polymorphism which is located in the three amino acids away from the thrombin acti...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2004-01, Vol.13 (1), p.32-35
Main Authors: Diz-Kucukkaya, R, Hancer, V S, Inanc, M, Nalcaci, M, Pekcelen, Y
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antiphospholipid Syndrome - genetics
Factor XIII - genetics
Female
Gene Frequency
Genotype
Humans
Leucine - genetics
Male
Middle Aged
Polymorphism, Genetic
Venous Thrombosis - etiology
Venous Thrombosis - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of thrombophilic mutations in the development of thrombosis in patients with antiphospholipid syndrome (APS) has been extensively investigated. Factor XIII (FXIII) Val34Leu polymorphism is a newly described polymorphism which is located in the three amino acids away from the thrombin activation site of the FXIII-A subunit. It has been reported that the Leu allele decreases the risk of both arterial and venous thrombosis. In the present study, we examined the associationbetween the FXIII Val34Leu polymorphismand the developmentof thrombosisin patients with APS. Sixty APS patients with arterial and venous thrombosis, 22 antiphospholipid antibody (aPLA) positive patients with first trimester abortus and/or thrombocytopenia,126 healthy controls, and 60 healthy subjects who were age- and sex-matched with thrombotic APS group were included into the study. FXIII Leu allele frequencies in the APS patients with thrombosis, aPLA-positive patients without thrombosis, healthy controls, and matched controls were 13.3, 16, 19.5, and 18.3%, respectively. When we compared Leu allele frequencies between APS patients with thrombosis and aPLA-positive patients without thrombosis, healthy controls or matched controls, we could not find any difference (x 2, P 0.43, and P 0.09, P 0.67, respectively). Our results showed that the FXIII Leu allele has no protectiveeffect in the developmentof thrombosis in APS.
ISSN:0961-2033
1477-0962
DOI:10.1191/0961203304lu479oa